Uwell Biopharma Inc.
TTPEX:790229.00
TWD
-0.20
(-0.68%)
ISIN
TW0007902009
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- New Taipei Taiwan
- Website
- uwell.com.tw
- Similar Companies
- Business
- Uwell Biopharma Inc. is a Taiwan-based biotechnology and medical device company engaged in the research, development, manufacturing, and commercialization of advanced biomaterials, surgical solutions, and regenerative medicine products. The company operates primarily through its Advanced Wound Care, Surgical Biomaterials, and Biomedical Contract Manufacturing segments. Its core product and service portfolio includes surgical anti-adhesion barriers and absorbable gels designed for post-operative tissue separation in abdominal and pelvic procedures; advanced wound management dressings comprising hydrogel dressings, silicone foam dressings, hydrocolloid matrices, and antimicrobial wound contact layers for acute, chronic, and post-surgical wounds; hyaluronic acid and collagen-based tissue engineering biomaterials for regenerative applications; specialized dermatological skin barrier formulations; and comprehensive original equipment manufacturing (OEM) and original design manufacturing (ODM) contract services for medical devices. Uwell Biopharma serves public and private hospitals, outpatient surgical centers, specialized clinics, and medical distributors across domestic and international healthcare markets. Founded in Taiwan and headquartered in Taipei, Taiwan, the company maintains GMP-compliant manufacturing infrastructure and ISO 13485-certified quality systems. In recent developments, Uwell Biopharma advanced its capital market presence through its listing on the Taipei Exchange under ticker 7902, expanded its commercial distribution networks across the Asia-Pacific region, entered into strategic partnerships to scale its absorbable biomaterial platforms, and broadened its commercial offerings by launching next-generation anti-adhesion formulations and expanding production capacity to support increasing demand for advanced surgical wound care solutions.